Focused On-demand Library for Small ribosomal subunit protein eS27

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P42677

UPID:

RS27_HUMAN

Alternative names:

40S ribosomal protein S27; Metallopan-stimulin 1

Alternative UPACC:

P42677; Q5T4L6

Background:

Small ribosomal subunit protein eS27, also known as 40S ribosomal protein S27 and Metallopan-stimulin 1, plays a crucial role in protein synthesis. It is a component of the small ribosomal subunit, essential for proper rRNA processing and maturation of 18S rRNAs. This protein is involved in the assembly of the SSU processome in the nucleolus, facilitating RNA folding, modifications, rearrangements, and cleavage.

Therapeutic significance:

Given its involvement in Diamond-Blackfan anemia 17, a condition characterized by congenital non-regenerative hypoplastic anemia, understanding the role of Small ribosomal subunit protein eS27 could open doors to potential therapeutic strategies. Its critical function in ribosome biogenesis and protein synthesis makes it a target for exploring treatments for this anemia and possibly other related disorders.